|
|
|
|
|
|
|
Free Newsletters
Archive
My Subscriptions
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers
Regional News
US & Canada
Biotech Bay
Biotech Beach
Genetown
Pharm Country
BioCapital
BioMidwest
Bio NC
BioForest
Southern Pharm
BioCanada East
US Device
Europe
Asia
Market Summary
News
IPOs
Company Profiles
Companies
Events
Research Store
Biotech Events
Post an Event
Real Estate
Business Opportunities
|
|
|
|
|
News | News By Subject | News by Disease |
News By Date | Search News
|
|
|
Market Update: Commonwealth Biotechnologies, Inc. (CBTE) Reports New Drug Discovery Contract Signings and Growth Initiatives
4/8/2008 8:38:32 AM
RICHMOND, Va.--(BUSINESS WIRE)--Commonwealth Biotechnologies, Inc. (“CBI”) (NASDAQ Capital Market:CBTE) is pleased to announce new signings and growth initiatives for its business units including Exelgen Ltd (“Exelgen”), CBI Services, Mimotopes Pty Ltd (“Mimotopes”), and Fairfax Identity Laboratories (“FIL”). Since December 2007, all four business units have executed significant drug discovery contracts with large pharmaceutical companies or major government agencies and embarked upon a range of growth initiatives. CBI management believes these results reflect a trend in the drug discovery outsourcing market to return to long-term, high quality outsourcing relationships in the industry. Dr. Paul D’Sylva, CEO of CBI, summarized the new announcements by saying, “Our Q1 signings demonstrate the strong drug discovery capabilities of the CBI Group and underscore the value of our drug discovery platforms and therapeutic area expertise. We are delighted to be working with new partners in the government and private sectors to discover novel drug candidates that will help to address unmet medical needs.”
|
|
|
|
|
|
|
|
|
|
|